Dishman Carbogen Amcis Ltd
Dishman Carbogen Amcis Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
2 of 5 strong
The short version
The company targets a consolidated revenue CAGR of approximately 15% over the next 2-3 years, higher than the 10-12% growth achieved previously. Revenue CAGR expected at ~15% over the next 3 years, higher than previous years (Page 28).
From Dishman Carbogen Amcis Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets a consolidated revenue CAGR of approximately 15% over the next 2-3 years, higher than the 10-12% growth achieved previously. (Page 28)
- India business aims to grow significantly, targeting INR 500 crores revenue by FY28, benefiting from tech transfers and multiple projects in the pipeline. (Pages 12, 18, 23)
- Stand-alone India revenue expected to increase in FY27 versus FY26, with potential to reach or exceed FY25 levels (~INR 400 crores) and grow further in FY28. (Page 19)
- CDMO segment to maintain approximately 85% share of revenues and grow steadily; marketable molecules about 15%. (Page 16)
- Margins in both CDMO and marketable molecule segments expected to improve, targeting 25% EBITDA margin by FY28. (Page 15)
- Growth driven by new contracts, increasing orders, and digital transformation initiatives without major CapEx increase. (Pages 18, 28)
- French entity's breakeven delayed but expected to improve due to combined drug substance and product offerings. (Page 28)
Profitability & Margins
See what Dishman Carbogen Amcis Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No major CapEx plans currently, except for co-investment with a Japanese innovator, where 100% of CapEx financing is by the partner (Page 18).
- Ongoing maintenance CapEx will continue group-wide.
- Investments planned in digital transformation, including SAP implementation across the group, lab management software, and exploring AI for process efficiencies (Page 18).
- The recent Swiss manufacturing line went live in Q4 FY25; no significant new fixed assets planned beyond current capacity (Page 9).
- Some CapEx may be required in the future, but not planned currently; financing sources considered cheap and flexible (Page 26).
- Tech transfer of a large molecule to India is a key strategic development expected to improve margins and scale India business (Pages 18, 22).
- Additional working capital and CapEx may be financed through new long-term borrowing approved by the Board (Page 8).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Dishman Carbogen Amcis Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company holds around INR 1,100 to INR 1,200 crores worth of Requests for Proposals (RFPs) in the India business.
- They expect to convert approximately 30-35% of these RFPs into firm orders.
- Physical inspection by a large innovator on a product’s active pharmaceutical ingredient is expected soon, which may translate into additional orders.
- New contracts and orders are in fluid stages; exact quarters of order fulfillment remain uncertain.
- For India, the target is to scale up revenue by INR 500 crores over the next 12 to 18 months.
- There is a tech transfer of one of the largest molecules from the Swiss entity to India, expected to increase margins despite giving discounts.
- Proposals have been made for late-phase and commercial projects in the French entity, with positive effects expected from combined drug substance and drug product offerings.
Dishman Carbogen Amcis Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹851 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Dishman Carbogen Amcis Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q2 FY26 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
- Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
- RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
- Sai Parenterals Ltd (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…
Frequently Asked Questions
What were Dishman Carbogen Amcis Ltd Q4 FY26 results?
The company targets a consolidated revenue CAGR of approximately 15% over the next 2-3 years, higher than the 10-12% growth achieved previously. Revenue CAGR expected at ~15% over the next 3 years, higher than previous years (Page 28).
What is Dishman Carbogen Amcis Ltd share price analysis?
Dishman Carbogen Amcis Ltd currently shows a below-average growth signal. The stock trades at a P/E of 164.8 with a market cap of ₹2,989 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dishman Carbogen Amcis Ltd planning capital expenditure?
No major CapEx plans currently, except for co-investment with a Japanese innovator, where 100% of CapEx financing is by the partner (Page 18).
Keep Dishman Carbogen Amcis Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.